Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week
study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients
with benign prostatic hyperplasia.